Jounce Therapeutics Appoints Barbara G. Duncan to its Board of Directors

CAMBRIDGE, Mass., May 25, 2016 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment, today announced the appointment of Barbara G. Duncan to the company’s board of directors. Ms. Duncan brings to the company almost 30 years of financial leadership experience, with over 15 of those years in management roles within the pharmaceutical industry.

“It is a great pleasure to welcome Barbara to our board of directors,” said Richard Murray, Ph.D., president and chief executive officer of Jounce. “Barbara’s proven record of success in leading financial and operational strategy in biotechnology and pharmaceutical companies will be indispensable as we continue to grow and advance our pipeline.”

Ms. Duncan has spent the last seven years as chief financial officer and treasurer at Intercept Pharmaceuticals, Inc. Previously, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., including as chief executive officer. Ms. Duncan began working in the healthcare industry in the corporate finance groups at SBC Warburg Dillon Read, Inc. and Lehman Brothers, Inc. She currently serves as a member of the board at Edgemont Pharmaceuticals, LLC, Medgenics, Inc. and Adaptimmune. Ms. Duncan received a masters of business administration from the Wharton School of the University of Pennsylvania and a bachelor of business administration from Louisiana State University.

“I am very excited to join the board of directors at a company looking to revolutionize cancer treatments by bringing new, innovative therapies to selected patient populations,” said Ms. Duncan. “Jounce has built a world-class team and completed impressive financings to-date, allowing them to advance their pipeline of innovative immunotherapies that target defined patient populations. I am eager to join the team as they continue to evolve their science and establish themselves as a key player in the immuno-oncology field.”

About Jounce Therapeutics
Jounce Therapeutics is an immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers, designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit


CONTACT: Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085